Editorial: Optimized gene-engineering and combination therapies to boost γδT cell immunotherapeutic performance

Marta Barisa; Daniel Abate-Daga; Jonathan Fisher

Abstract

Linked entities

Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.

Genes25

CEP70 AKT1 Fdps NCR2 TRBV20OR9-2 FCGR3A Tnfrsf17 Klrk1 Kdr CXADRP1 Cd274 CCL2 IL17A Ifng Cd19 FLT1 Cd247 PIK3CD KIT LAG3 Il17a Cd226 CD274 KDR Il2

Proteins22

Species2

Homo sapiens(human · species)Mus musculus(house mouse · species)

Cell lines3

THP-1— Homo sapiens (Human) · Childhood acute monocytic leukemia · Cancer cell line NSG— Homo sapiens (Human) · Glioblastoma · Cancer cell line CAR-T— Mus musculus (Mouse) · Transformed cell line

Chemicals6

lipid RPMI1640 IPP cholesterol zoledronic acid sulfatide

Diseases11

acute myeloid leukaemia multiple myeloma cytotoxicity mesothelioma non-small cell lung carcinoma leukaemia breast cancer cancer AML B cell malignancies GvHD

Peer Reviews

No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.

Videos

No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.

Taxonomy

TopicsCAR-T cell therapy research · Immune Cell Function and Interaction · Immunotherapy and Immune Responses